Early-stage biotech: The wrong outsourcing strategy costs more than time

For early-stage biotech companies, innovation is just the beginning—the greater challenge lies in navigating the complex development path with limited time, resources, and visibility. Fragmented outsourcing and siloed decision-making can create costly delays, misalignment, and missed milestones. Success depends on more than great science; it requires a cohesive model that links strategy and execution across every phase of development. By aligning early decisions with downstream outcomes, biotechs can accelerate progress, reduce risk, and preserve continuity from preclinical through clinical stages.

Thermo Fisher Scientific’s Accelerator™ Drug Development framework unites clinical research, manufacturing, and supply chain under one partner to simplify this journey. Backed by data from the Tufts Center for the Study of Drug Development, the integrated model has been shown to shorten timelines, enhance portfolio value, and strengthen decision-making. With clear oversight, adaptive flexibility, and seamless continuity, early biotechs can move from concept to first-in-human trials with greater speed and confidence.